What Tigreat Treats: Main Uses and Benefits

Tigreat is indicated for the acute management of moderate or severe migraine headache attacks in adults, including those that manifest with or without an aura. It is commonly used across conditions presenting with acute episodes and is considered relevant when supportive symptom management is appropriate to interrupt the attack once the pain has begun. The medication is relevant for easing intense, throbbing head pain, along with associated distressing manifestations such as nausea, vomiting, photophobia (light sensitivity), and phonophobia (sound sensitivity).

---

Relief and Contextual Use

This treatment is typically applied during the acute phase of a migraine when symptoms are creating noticeable functional strain. It provides support that helps ease the overall symptom burden, and may assist with maintaining functional stability during periods of heightened symptoms. Given its application in sustained symptom management, Tigreat is generally applied in scenarios where sustained relief is a priority, such as with menstrually related migraines or other attacks prone to relapse, and is used for managing the risk of the headache returning.

Quick Fact: Relief for Headache Pain Tigreat is relevant for easing the symptoms of severe head pain associated with migraine, assisting with the management of acute episodes.

Regulatory References

1. NIH DailyMed official prescribing information

The use of this medicine (osimertinib) is strictly determined by regulatory rules defining patient eligibility, based on laboratory confirmation and absence of specific risk factors or conditions.

Mandatory Eligibility and Age:

• The patient must be an adult and must have their tumor status confirmed as positive for specific EGFR mutations (e.g., Exon 19 deletions, L858R substitution, or T790M mutation) by an approved test.
• Use in the pediatric population (under 18 years of age) is not established and is not recommended.

Contraindications and Prohibited Use:

• Use is contraindicated in patients with a known hypersensitivity to the drug or any of its ingredients.
• It must not be used concurrently with the herbal product St. John’s Wort.
• Use is prohibited during pregnancy (due to potential fetal harm) and breastfeeding (must be discontinued).

Restrictions and Conditional Use:

• Patients with severe hepatic impairment or end-stage renal disease (creatinine clearance < 15 mL/min) are generally not recommended to use the medicine due to insufficient data.
• Patients with pre-existing cardiac conditions (e.g., congenital long QTc syndrome, congestive heart failure) or electrolyte abnormalities require careful monitoring.

Interactions with other medicines and products

The interaction profile for Tigreat (Frovatriptan) is governed by two primary regulatory concerns: pharmacodynamic risk and pharmacokinetic modification. Certain combinations are formally contraindicated due to the potential for severe additive effects. Frovatriptan must not be co-administered with Ergotamine or other Ergotamine derivatives, nor with other 5-HT1 agonists (Triptans). A strict time interval of at least 24 hours is required between administering Frovatriptan and any of these compounds to avoid the risk of additive vasospastic effects.

A second critical pharmacodynamic interaction involves agents that increase central serotonin activity. Co-administration with Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAOIs), or Tricyclic Antidepressants (TCAs) is associated with the documented risk of developing Serotonin Syndrome. This risk of undesirable effects is also noted with the co-administration of the herbal product St John’s Wort.

Pharmacokinetic interactions occur primarily via the CYP1A2 enzyme pathway. The potent CYP1A2 inhibitor Fluvoxamine significantly increases Frovatriptan’s systemic exposure (AUC and Cmax). Other substances documented to increase plasma concentrations include Oral Contraceptives and Propranolol. Finally, use of Frovatriptan is contraindicated in patients with Severe Hepatic Impairment (Child-Pugh C), reflecting the heightened risk of adverse effects from altered drug clearance.

Targeted Serotonin Receptor Agonism

Frovatriptan operates as a selective agonist at two key receptor subtypes within the serotonergic system: 5- HT1 B and 5- HT1 D receptors. By binding to these specific targets, the molecule initiates an inhibitory signaling cascade at the molecular level. This targeted engagement is necessary to influence the activity within the affected physiological pathways.

---

Dual Modulation of Vasculature and Neurogenic Signaling

The mechanism exerts a dual effect critical for interrupting the signaling cascade within the trigeminovascular system. Activation of the 5- HT1 B receptors on cranial vessel walls leads to vasoconstriction, while activation of 5- HT1 D receptors on trigeminal nerve endings results in presynaptic inhibition . This combined action leads to 5- HT1 B-mediated contraction of pathologically dilated vessels and 5- HT1 D-mediated inhibition of pro-inflammatory mediator release, such as Calcitonin Gene-Related Peptide (CGRP). This physiological change results in a reduction of mediator activity and influences the regulatory state within the affected pathways.

---

Sustained Systemic Effect

The mechanistic profile is characterized by a unique binding dynamic that influences a prolonged engagement with the trigeminovascular targets. This prolonged target engagement sustains the physiological adjustment achieved through vasoconstriction and neuropeptide suppression, occurring in pathways where extended activity at the targets is observed.

How to Use Tigreat

The administration of Tigreat (Frovatriptan 2.5 mg) is governed by specific instructions for the acute treatment of migraine attacks. It is supplied as an oral tablet and is not intended for the prevention of migraine.

---

Administration Protocol

Entity	Official Instruction
Route of Administration	Oral (swallowed whole with fluids).
Dosing Schedule	A single 2.5 mg tablet is the recommended starting dose. The total dose must not exceed 7.5 mg (three 2.5 mg tablets) within a 24-hour period.
Timing and Frequency	The tablet should be taken as soon as possible after the onset of the migraine headache pain, not during the aura phase alone.
Repeat Dose Interval	If the headache is relieved but returns, a second 2.5 mg tablet may be taken after an interval of at least 2 hours. There is no evidence that a second dose is effective if the first dose provided no initial relief for the same attack.
Food Relation	The medication can be administered with or without food.

---

Use Constraints

The use of this medicine is subject to defined constraints. The safety of treating an average of more than four migraine attacks in a 30-day period has not been established. Furthermore, official instructions advise against use for 10 or more days per month due to the risk of medication overuse headache.

• Hepatic/Renal Status: No dose adjustment is required for patients with mild to moderate renal or hepatic impairment. Use is not recommended in cases of severe hepatic impairment.
• Age: Use is not recommended in pediatric patients (under 18 years) or in adults over 65 years due to limited clinical experience and safety data in these populations.

Research Evidence / Overview of Studies for Tigreat (Frovatriptan)

---

Evidence for Acute Treatment of Moderate or Severe Migraine

Research on Tigreat has primarily involved short-term, randomized, placebo-controlled trials, which are a common design used in research exploring how symptoms change over time in a specific population. The main outcomes research examined included measurements of symptom intensity or variability, such as the proportion of participants reporting symptoms shifting from moderate/severe to mild/none at two hours, and the complete absence of pain at the same time point. Studies monitored not only the head pain but also associated outcomes related to systemic or functional imbalance related to nausea, vomiting, and light and sound sensitivity.

Findings data show patterns related to outcomes related to physical discomfort in the observed populations. These comparative trials described patterns such as variation in the time to pain-free status measurement across treatments. The overall research provides context but not individual predictions about initial episodic or acute changes.

---

Evidence Supporting Sustained Relief and Low Recurrence

A key focus of the research was the long-duration monitoring, which is particularly relevant in trials assessing short-term or episodic symptom patterns prone to relapse. Studies monitored participants over 24 hours and 48 hours to track a critical secondary outcome describing episodic or acute changes: headache recurrence. This finding contributes to understanding symptom patterns.

---

Research on Intermittent Use for Menstrually Related Migraine (MRM)

Tigreat was studied for a specific approach to conditions characterized by fluctuating or episodic manifestations, particularly menstrually related migraine (MRM). The primary outcomes research examined were the number and severity of migraine attacks that occurred during the treatment window. The findings describe patterns observed in the studies, which contribute to the broader evidence landscape for conditions involving periods of heightened symptoms.

---

Research Gaps and Remaining Uncertainties

While there is a substantial body of evidence for the acute treatment of migraine, several research limitations frames apply. For instance, long-term effects are not fully established regarding the use of Tigreat for frequent management over many years. Furthermore, the follow-up durations were limited to 48 hours in the core efficacy trials. Comparative evidence is lacking against every other available triptan in direct head-to-head trials. Finally, the initial study population was homogenous in terms of age and ethnic background, meaning subgroup findings are uncertain for populations not well represented in the initial randomized trials.

Key Studies & References

1. FROVA® (frovatriptan succinate) Tablets - DailyMed

Common questions about Tigreat (FAQ)

Q: How quickly does Tigreat start working after you take it?

A: Studies and official information indicate that Tigreat is intended for use as soon as possible after the migraine headache pain begins. While individual response times may vary, clinical trials often measure how quickly patients become pain-free or have their pain reduced, with key efficacy outcomes typically assessed at two hours following administration.

Q: Are there any long-term side effects associated with Tigreat use?

A: The primary safety data for this medication comes from short-term clinical trials. Regulatory documents caution that the safety of treating an average of more than four migraine attacks in a 30-day period has not been established. Frequent use may also lead to a condition known as medication overuse headache.

Q: Will Tigreat affect my ability to drive or operate machinery?

A: Official product information notes that dizziness and fatigue are reported as common side effects associated with the use of this drug. Official labeling indicates that caution should be exercised when engaging in tasks requiring mental alertness, such as driving or operating machinery, until an individual knows how the drug affects them.

Q: Does Tigreat interact with birth control pills?

A: Yes, official regulatory documents state that oral contraceptives are known to increase the amount of Frovatriptan (the active ingredient in Tigreat) in the bloodstream. Regulatory documents indicate that co-administration with oral contraceptives can result in increased systemic exposure to the drug.

Q: What studies have been published regarding Tigreat's long-term safety?

A: While the core clinical evidence establishes the drug's short-term effectiveness for acute migraine, regulatory warnings advise caution for patients with pre-existing cardiovascular risk factors. Official labels state that for these individuals, monitoring or periodic cardiovascular evaluations are warranted while using the medication, particularly with long-term intermittent use.

Q: What is the typical duration of treatment with Tigreat?

A: Tigreat is intended for the acute relief of migraine episodes, not continuous daily use. Regulatory documents warn against the use of the drug for more than ten days per month to mitigate the risk of developing a condition known as medication overuse headache. The safety of treating more than four migraines in 30 days is also not established.

Q: Is Tigreat safe to use during pregnancy?

A: Regulatory documents state that there are no adequate and well-controlled studies of Tigreat in pregnant women. Based on animal studies, there is a potential for the drug to cause harm to the developing fetus. The decision to use the medication during pregnancy requires a careful assessment of the potential benefits versus the potential risks.

Q: Is Tigreat excreted in breast milk, and is it safe for nursing mothers?

A: Studies in animals show that the drug is excreted into the milk of lactating rats. Official labels include a recommendation to avoid breastfeeding for 24 hours after taking the medication, given the potential for serious adverse reactions in a nursing infant.

Q: Can I stop taking Tigreat abruptly, or do I need to taper off?

A: Tigreat is taken only when a migraine occurs, so it is not a drug that requires a typical 'tapering' off schedule. However, if the drug is used too frequently, leading to a condition called medication overuse headache, regulatory documents indicate that detoxification may be necessary to resolve the condition.

Q: Does Tigreat show up on standard drug tests?

A: Tigreat (Frovatriptan) is a triptan medication used for migraines. Official sources confirm it is not classified as a controlled substance by the U.S. Food and Drug Administration (FDA) and is not an opioid or narcotic.

Q: Can taking Tigreat make you feel anxious or agitated?

A: Official product information catalogs anxiety and agitation as side effects that have been reported by less than 1% of patients in clinical trials. Individuals who experience unusual changes in mood or behavior should seek guidance from a healthcare professional.

Q: What happens if I accidentally take two doses of Tigreat close together?

A: The official administration instructions for Tigreat require an interval of at least two hours between the first tablet and a second tablet if the migraine returns. Official regulatory documents indicate that doses taken closer than two hours apart are outside of the established dosing schedule.

Q: Is Tigreat available over the counter anywhere?

A: No, according to official regulatory information, the active ingredient, Frovatriptan, is classified as a prescription-only drug in the United States and is not currently available over-the-counter.

Q: What percentage of patients experience severe side effects on Tigreat?

A: Official labels report the frequency of adverse reactions using categories (such as common or uncommon). While a specific overall percentage for 'severe side effects' is not published, the frequency of specific serious adverse reactions (such as heart-related events) is noted in regulatory post-marketing reports as being rare.

Storage and Disposal Requirements for Tigreat (Frovatriptan Succinate)

Storage Conditions

Tigreat tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be protected from freezing, excess heat, and moisture. Always keep the medication in the container it came in, with the lid tightly closed.

Requirement	Condition
Temperature	Controlled Room Temperature (20 C–25 C)
Protection	Keep from Freezing, Heat, and Moisture

Handling and Disposal

For stability, do not use Tigreat after the expiry date printed on the package. The tablets must be stored securely out of the sight and reach of children. Unused or expired tablets should be disposed of in accordance with local regulations. Do not dispose of the medication by pouring it into a drain or flushing it down the toilet.